Literature DB >> 7648989

Development of transient autoimmune hepatitis during interferon treatment of chronic hepatitis B.

J Cianciara1, T Laskus.   

Abstract

A 42-year-old man was treated with interferon-alpha for chronic hepatitis B; during the fourth week of treatment he developed an exacerbation of liver disease, and nuclear and smooth muscle autoantibodies, which were previously negative, were detected in very high titers. After discontinuation of interferon therapy, ALT values subsided promptly and autoantibodies disappeared within a few months. This sequence of events strongly suggests a direct relationship between IFN treatment and a self-limited hepatitis with autoimmune markers in this case.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7648989     DOI： 10.1007/bf02212711

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


  20 in total

1.  Thrombocytopenia during interferon alfa therapy.

Authors:  J H Hoofnagle
Journal:  JAMA       Date:  1991-08-14       Impact factor: 56.272

2.  Autoimmune chronic hepatitis type 2 manifested during interferon therapy in children.

Authors:  M Ruiz-Moreno; M J Ruá; V Carreño; J A Quiroga; M Manns; K H Meyer zum Büschenfelde
Journal:  J Hepatol       Date:  1991-03       Impact factor: 25.083

3.  LKM1 appearance in a HLA-DR3+ patient with chronic hepatitis C during interferon treatment.

Authors:  L Muratori; D Zauli; F Giostra; G Ballardini; M Lenzi; F Cassani; F B Bianchi
Journal:  J Hepatol       Date:  1993-06       Impact factor: 25.083

Review 4.  Interferons, a group of multiple lymphokines.

Authors:  H Kirchner
Journal:  Springer Semin Immunopathol       Date:  1984

5.  Autoimmune thyroid disease in interferon-treated patients.

Authors: 
Journal:  Lancet       Date:  1985-07-13       Impact factor: 79.321

6.  Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis.

Authors:  W J Mayet; G Hess; G Gerken; S Rossol; R Voth; M Manns; K H Meyer zum Büschenfelde
Journal:  Hepatology       Date:  1989-07       Impact factor: 17.425

7.  Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy.

Authors:  K C Conlon; W J Urba; J W Smith; R G Steis; D L Longo; J W Clark
Journal:  Cancer       Date:  1990-05-15       Impact factor: 6.860

8.  Nucleotide sequence analysis of the precore region in patients with fulminant hepatitis B in the United States.

Authors:  T Laskus; D H Persing; M J Nowicki; J W Mosley; J Rakela
Journal:  Gastroenterology       Date:  1993-10       Impact factor: 22.682

9.  Inhibition of the T suppressor circuit of delayed-type hypersensitivity by interferon.

Authors:  J Knop; R Stremmer; U Taborski; W Freitag; J de Maeyer-Guignard; E Macher
Journal:  J Immunol       Date:  1984-11       Impact factor: 5.422

Review 10.  Interferons and autoimmunity.

Authors:  A Schattner
Journal:  Am J Med Sci       Date:  1988-06       Impact factor: 2.378
View more
  3 in total

1.  STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiological actions of IFN-alpha in the central nervous system.

Authors:  Jianping Wang; Robert D Schreiber; Iain L Campbell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-02       Impact factor: 11.205

Review 2.  Cytokine-induced autoimmune disorders.

Authors:  P Miossec
Journal:  Drug Saf       Date:  1997-08       Impact factor: 5.606

Review 3.  Concurrent emergence of hepatitis B e antigen-negative hepatitis B virus variant and autoimmune hepatitis cured by adenine arabinoside monophosphate.

Authors:  H Bécheur; D Valla; M A Loriot; A Attar; F Bloch; J P Petite
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.